MannKind Corporation Reports 2015 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Maintains Underweight on MannKind (MNKD) Following Results and Grim Outlook
November 10, 2015 7:01 AM ESTPiper Jaffray analyst Joshua Schimmer reiterated an Underweight rating and $1.50 price target on MannKind (NASDAQ: MNKD) following results.
Schimmer commented, "While cost-cutting measures will help curtail the cash burn, the disappointing launch of Afrezza and increasing net-debt position seem to be making the... More
Leerink Partners' Ominous Sign on MannKind (MNKD)
November 9, 2015 11:29 AM ESTIn addition to poor earnings, MannKind (NASDAQ: MNKD) investors are reacting to the ominous sign from Leerink Partners' Sanofi (NYSE: SNY) analyst Seamus Fernandez.
Fernandez removed Afrezza estimates from their Sanofi 2016 model and... More
MannKind (MNKD) Mentioned Cautiously on Twitter
November 9, 2015 11:26 AM ESTMannKind (NASDAQ: MNKD) was mentioned cautiously on Twitter by theStreet columnist Adam Feuerstein.
. @shaneblackmon $MNKD has to address the bankruptcy question on tonights call. Theyre very close to insolvency. How will co. survive?
Adam Feuerstein (@adamfeuerstein) November 9, 2015
MannKind (MNKD) Misses Q3 EPS by 1c
November 9, 2015 10:18 AM ESTMannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).
For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product... More
